导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.42% | 3655/4773 |
| 近一周 | -3.32% | 4053/5462 |
| 近一月 | -3.11% | 1561/5421 |
| 近一季 | -6.24% | 2026/5209 |
| 近半年 | -18.25% | 4254/4920 |
| 近一年 | -7.85% | 3243/4366 |
| 近两年 | 21.99% | 2610/2954 |
| 近三年 | -5.18% | 1992/2253 |
| 成立以来 | -4.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.11% 1056/4961 |
-6.27% 3683/5312 |
- - |
- - |
| 2025 | 4.61% 3039/4813 |
-6.31% 3348/3635 |
1.97% 1980/4076 |
9.35% 3364/4524 |
0.13% 2193/4813 |
| 2024 | 12.56% 1233/3463 |
3.99% 491/2808 |
-0.04% 671/3014 |
8.24% 2759/3129 |
0.04% 1282/3463 |
| 2023 | -7.38% 916/2656 |
12.43% 293/2280 |
0.42% 322/2385 |
-6.38% 1473/2515 |
-12.38% 2458/2655 |
| 2022 | -11.68% 252/2207 |
-4.04% 162/1919 |
1.50% 1467/2016 |
-11.99% 623/2113 |
3.03% 783/2208 |
| 2021 | 23.31% 131/1822 |
7.09% 84/1255 |
-3.21% 1240/1330 |
18.70% 60/1466 |
0.23% 1157/1822 |
| 2020 | -6.28% 974/1250 |
-5.52% 427/1028 |
-4.86% 1045/1067 |
7.52% 775/1164 |
-3.04% 1126/1184 |
| 2019 | 2.13% 808/1092 |
17.03% 663/739 |
-10.48% 741/788 |
-4.09% 759/850 |
1.64% 874/918 |
| 2018 | - - |
- - |
-18.13% 600/631 |
3.07% 87/660 |
-8.41% 92/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证基建工程ETF联接C VS. 长安沪深300非周期A(740101) |